GWAS defines pathogenic signaling pathways and prioritizes drug targets for IgA nephropathy

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The study was founded by Columbia University, Columbia Glomerular Center, IGA Nephropathy Foundation of America, and National Institute for Diabetes and Digestive Kidney Diseases (NIDDK) grants R01DK105124 and RC2DK116690, R01DK082753. Additional support was provided by R01LM013061, U01HG008680, U01AI152960, R01DK078244, R01AI149431, National Science Foundation of China (82022010, 82070733); Beijing Natural Science Foundation (Z190023); DFG Project ID 192904750 CRC 992 Medical Epigenetics, DFG Project ID 431984000 CRC 1453, and the EQUIP Program for Medical Scientists, Faculty of Medicine, University of Freiburg. JBH, SP, KL, and WM were supported by R01HG010730, U01AI130830, R01NS099068, R01AI024717, R01AR073228, U01AI150748, R01AI148276, P01AI150585 and the US Department of Veterans Affairs Merit Award I01BX001834 to JBH. DPG was supported by the St Peter's Trust for Kidney, Bladder and Prostate Research. The UK cohort data was generated as a result of a grant from Kidney Research UK and the Medical Research Council (JB and DG). The German STOP-IgAN study was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) CRU 5011 and Project ID 445703531. The GCKD (German Chronic Kidney Disease) study was funded by grants from the German Ministry of Education and Research (BMBF, No. 01ER0804) and the KfH Foundation for Preventive Medicine.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All subjects provided informed consent to participate in genetic studies, and the Institutional Review Board (IRB) of Columbia University as well as local ethics review committees for each of the individual cohorts approved our study protocol.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes